# QUALITY CHOICE MUCUS RELIEF PE PE- guaifenes in/phenylephrine tablet Chain Drug Marketing Association

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

-----

#### **DRUG FACTS**

**Active ingredient** - (per tablet)

Guaifenesin 400 mg

Phenylephrine HCl 10 mg

#### **Purpose**

Guaifenesin.....Expectorant

Phenylephrine HCl.....Nasal decongestant

#### Uses

Temporarily relieves symptoms associated with a cough ,the common cold,hay fever or other upper respiratory allergies.

- helps loosen phlegm (mucus)
- clear nasal passageways
- loosens nasal congestion
- drain bronchial tubes
- shrinks swollen membranes
- clears stuffy nose
- makes coughs more productive

### Warnings

Do not exceed recommended dosage

#### Do not use

■ this product if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression,

psychiatric or emotional conditions, or Parkinson's Disease), or for 2 weeks after stopping the MAOI drug. If you are uncertain whether your prescription drug contains an MAOI, ask a health professional.

### Ask a doctor before use if you have

- heart disease
- high blood pressure
- thyroid disease
- diabetes

- excessive phlegm;mucus
- difficulty in urination due to an enlarged prostate gland
- persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis or emphysema

### Stop use and ask a doctor if

- nervousness, dizziness or sleeplessness occurs
- symptoms are accompanied by fever, rash, persistent headache or excessive phlegm (mucus)
- cough and congestion do not improve within 7 days or tend to recur.

These could be signs of a serious condition.

**If pregnant or breast-feeding**, ask a health professional before use.

**Keep out of the reach of children.** In case of overdose, get medical help or contact a Poison Control Center immediately.

#### **Directions**

- adults and children 12 years and over: take 1 caplet every 4 hours as needed
- children 6 to under 12 years:

take 1/2 caplet every 4 hours as needed

■ children under 6 years: consult a doctor

Do not exceed 6 doses in a 24 hour period or as directed by a doctor.

#### **Inactive ingredients**

lactose, magnesium silicate, croscarmellose sodium, hypromellose, magnesium stearate, maltodextrin, microcrystalline cellulose, mineral oil, povidone, silica, sodium lauryl sulfate, stearic acid, titanium dioxide and triacetin



## QUALITY CHOICE MUCUS RELIEF PE PE

guaifenesin/phenylephrine tablet

Product Information			
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:63868-752
Route of Administration	ORAL		

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
Guaifenesin (UNII: 495W7451VQ) (Guaifenesin - UNII:495W7451VQ)	Guaifenesin	400 mg		
PHENYLEPHRINE HYDRO CHLO RIDE (UNII: 04JA59TNSJ) (PHENYLEPHRINE - UNII: 1WS297W6MV)	PHENYLEPHRINE HYDROCHLORIDE	10 mg		

Inactive Ingredients			
Ingredient Name	Strength		
CROSCARMELLOSE SODIUM (UNII: M28 O L1HH48)			
LACTOSE (UNII: J2B2A4N98G)			
MALTO DEXTRIN (UNII: 7CVR7L4A2D)			
CELLULOSE, MICRO CRYSTALLINE (UNII: OP1R32D61U)			
MINERAL OIL (UNII: T5L8T28FGP)			
PO VIDO NE (UNII: FZ989 GH94E)			
MAGNESIUM SILICATE (UNII: 9B9691B2N9)			

#### MAGNESIUM STEARATE (UNII: 70097M6I30)

Product Characteristics			
Color	white	Score	2 pieces
Shape	OVAL	Size	17mm
Flavor		Imprint Code	RCCGPE;C27
Contains			

P	Packaging			
#	Item Code	Package Description	<b>Marketing Start Date</b>	Marketing End Date
1	NDC:63868-752-50	1 in 1 CARTON		
1		50 in 1 BOTTLE		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part341	06/05/2006	

# Labeler - Chain Drug Marketing Association (011920774)

# Registrant - Reese Pharmaceutical Co (004172052)

Establishment				
Name	Address	ID/FEI	Business Operations	
Reese Pharmaceutical Co		004172052	relabel(63868-752), repack(63868-752)	

Revised: 4/2014 Chain Drug Marketing Association